181 results about "Cellular secretion" patented technology

Methods, systems, and devices for enumerating the number of cells present in each event for cell-secretion based sorting applications are described herein. The cell secretion applications use carrier to encapsulate cells and collect the biomolecules they secrete. The carriers are then sorted using flow based particle sorting. The total number of cells present in a carrier is very important for several applications. A convolutional neural network is used to count the number of cells present from a brightfield image, and outputs the information to be used as part of the sort logic.

The present invention discloses a preparation method of Inonotus hispidus polysaccharide IHP-1aa: It is obtained by removing fat with ethanol, extracting with water and precipitating with ethanol, then removing proteins by the Sevage method, separating neutral polysaccharide components through a DEAE-52 cellulose column and a DEAE agarose gel column, and finally purifying with Sephadex G-100. The Inonotus hispidus polysaccharide has uniform purity and clear composition, and is a heteropolysaccharide composed of glucose, galactose, mannose, fucose and methylgalactose, with a molecular weight of 26.9 kDa. In vitro experiments show that it has no adverse effects on normal cells, can significantly stimulate macrophages RAW264.7 to secrete NO, IL-6 and TNF-α, has good immunomodulatory activity, and can be used for the development of immunomodulatory products.

The invention provides brain cell specific targeting delivery based on exosome, and the exosome secreted by 293T cells is used for engineering transformation, so that the capabilities of penetrating BBB and specifically targeting neurons are achieved. According to the present invention, the L1CAM is loaded on the exosome, the exosome is obtained by transfecting a 293T cell of a Lamp2b-L1CAM PCDH-HygroHA plasmid through a 293T-Lamp2b-L1CAM cell line, and the BBB cell-penetrating peptide 4F-T7 and the neuronal targeting protein L1CAM are loaded on the surface of the exosome so as to treat the neurodegenerative diseases such as the Alzheimer's disease and the Parkinson's disease.

A secretion analysis and sorting system where cell(s) are deposited into a carrier that will capture any secretions from the cell, and is small enough to be sorted using flow cytometry based cell sorting, is described herein. The use of an image classification workflow that identifies the event types present in a sample of carriers allows the user to select which event types they would like to purify, and then train a supervised classification system that will be used to make real time sort decisions to purify the carriers which contain cells that secrete the desired product. A flow cytometer is then able to be used to screen the individual carriers to see if each one has the desired secreted product.

The invention relates to the technical field of medical cosmetology, in particular to a porous hollow glass bead capable of slowly releasing collagen and application of the porous hollow glass bead. The porous hollow glass bead capable of slowly releasing the collagen comprises a porous hollow glass bead body, the outer wall of the porous hollow glass bead body is provided with a pore channel structure penetrating through the exterior and an inner cavity of the hollow glass bead body, and the pore channel and the inner cavity of the porous hollow glass bead body are filled with collagen gel. The compressive strength of the hollow glass beads is utilized to improve the mechanical supporting effect, the collagen gel is subjected to catalytic decomposition under the action of collagenase in a body so as to achieve the slow-release effect, the outer walls of the hollow glass beads slow down the reaction time through physical isolation, and then the slow-release time is prolonged; meanwhile, ions such as Si and Ca released by the hollow glass beads can promote cells to secrete collagen, the biological activity is improved, and the three beneficial effects of physical support, collagen slow release and biological safety are achieved.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The invention relates to application of a palmitoylation inhibitor in preparation of a medicine for treating spontaneous abortion. The palmitoylation inhibitor is 2-BP (2-Butyl Phosphate). The spontaneous abortion is recurrent abortion caused by unknown reasons. The 2-BP is used for promoting the dCD4 < + > T cells to secrete Th2 and Treg type cell factors. The 2-BP reduces embryo loss and promotes the tolerance phenotype of dCD4 + T cells, facilitating maternal-fetal immune tolerance. The invention provides an application of 2-BP in a medicine for treating spontaneous abortion. In particular, in-vitro experiments and animal experiments prove that 2-BP promotes Th2-type bias and Treg amplification of dCD4 + T cells, reduces embryo absorption and improves bad pregnancy outcome.

The present invention relates to the new use of an exosome secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and in particular relates to the use of the exosome in the preparation of a drug for treating liver diseases. The exosome is secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and the hepatocyte lineage cells are hepatic progenitor cells and / or mature hepatocyte-like cells.

The invention belongs to the technical field of biotechnology and tissue engineering, and particularly relates to application of pilose antler bud cell secretions in preparation of anti-osteoporosis drugs. The pilose antler bud cell secreta is obtained by adopting gradient centrifugation, and cell experiments show that the pilose antler bud cell secreta provided by the invention has the effect of promoting osteogenic differentiation of cells; animal experiment results show that the cornu cervi pantotrichum bud cell secreta provided by the invention can significantly improve the bone mineral density, bone volume fraction, bone trabecula number, bone trabecula thickness, bone trabecula separation degree and cortical bone mineral density of mice, increase the bone trabecula area of primary osteogenesis and secondary osteogenesis centers of the mice, improve osteoporosis symptoms of the mice, and improve osteoporosis of the mice. The effect is obviously better than that of bone marrow mesenchymal stem cell secretions, part of indexes are equivalent to the treatment effect of diphosphates, and the antler bud cell secretions provided by the invention can be used for preparing medicines for preventing, relieving or treating osteoporosis.

The invention relates to the technical field of cell biology, in particular to application of a composition containing a mesenchymal stem cell secretor in pulmonary fibrosis. A systematic pharmacodynamic experiment verifies that the composition can remarkably reduce the content of a key fibrosis promoting factor TGF-beta1 in the blood of a pulmonary fibrosis model rat and effectively improve the blood-gas exchange function at the same time, and the blood oxygen saturation (SaO2) is remarkably increased, and the partial pressure of carbon dioxide (pCO2) is remarkably reduced. The improvement of the key indexes proves that the composition has a definite anti-fibrosis effect and a lung function protection effect, and a brand new treatment strategy is provided for pulmonary fibrosis diseases which lack special-effect treatment clinically at present. The technology not only has a remarkable clinical transformation value, but also develops an innovative research thought for the lung disease treatment field based on the action mechanism of the stem cell secretor, and has important scientific significance and market development prospect.

Systems, methods, compositions, and kits for measuring secreted factors from cells are disclosed herein, including those capable of determining single cell secretion activity and protein expression and / or gene expression simultaneously. Disclosed herein include solid supports comprising a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. Also disclosed herein include secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe. A secreted factor-binding reagent can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

The invention relates to a micro-fluidic chip for chemiluminescence imaging detection of single-cell secretions and a use method of the micro-fluidic chip. The micro-fluidic chip is composed of a single cell analysis layer and a glass substrate layer. The single cell analysis layer is prepared from polydimethylsiloxane and is provided with a capture channel, a sample introduction channel and a lantern-shaped microstructure array, the lantern-shaped microstructure comprises a small-size cell capture trap and a large-size chemiluminescence detection chamber, the small-size cell capture trap is connected with the capture channel, and the large-size chemiluminescence detection chamber is connected with the sample introduction channel. After a mixed solution of cells and a detection reagent is introduced into the capture channel, single cell capture is realized on the capture trap due to flow resistance difference; then, introducing air into the capture channel and the sample introduction channel to form a gas-in-liquid microcavity, and carrying out single cell isolation and incubation reaction; finally, the signal switch molecules and the substrate liquid are sequentially injected into the chemiluminescence detection chamber through the sample injection channel, and quantitative detection is conducted on the single-cell secretions according to chemiluminescence imaging signals.

The invention belongs to the field of functional polypeptide preparation, and particularly relates to euphausia superba peptide and application thereof in preparation of immunomodulatory drugs. The euphausia superba peptide is prepared from the following peptide fragments: DIFDPL (Diaphragmitic Induced Factor Dinucleotide Lipoprotein Lipoprotein), KPWALT (Keylanine White Amplified Transcription), LPFQRL (Lipoprotein Lipoprotein Quantitative Reducing Lipoprotein), FYFF (Factor Yeast Factor The Antarctic krill mixed peptide sample prepared by the invention has no cytotoxicity, and can promote cell proliferation, enhance cell NO secretion, improve cell phagocytic ability and effectively enhance immunity. The euphausia superba peptide prepared in the invention is easier to absorb, and has significant reduction and oxidation resistance. The polypeptide provided by the invention is a functional influence factor which has huge potential in the aspect of enhancing immunity, different bioactive peptides have different action mechanisms due to amino acid composition and structural characteristics, and theoretical support is provided for further developing food for enhancing the immunity function by utilizing the euphausia superba peptide. The development value of the euphausia superba is improved.

The present invention discloses an anti-inflammatory peptide derived from quinoa and its use, belonging to the field of polypeptides. The technical problem to be solved by the present invention is how to inhibit the secretion of inflammatory mediators by immune cells. The polypeptide provided by the present invention (polypeptide SCAWLLAWSAPK) has an amino acid sequence as shown in SEQ ID NO: 1. The present invention also protects pharmaceutically acceptable salts of the polypeptide. The present invention also protects the use of the polypeptide or pharmaceutical salt in the preparation of products (such as drugs, reagents, or preparations) that inhibit inflammation. The inhibition of inflammation is manifested by inhibiting the secretion of inflammatory mediators by immune cells.

The application belongs to the technical field of medicine, and discloses a class of alkaloid compounds and the use of pharmaceutical compositions thereof in treating inflammation. In vitro cell experiments prove that the components have a significant inhibitory effect on the secretion of important inflammatory factors TNF-alpha and NO of lipopolysaccharide-induced RAW264.7 cells, and have a significant down-regulation effect on the phosphorylation level of key proteins of the NF-kappa B pathway in the inflammatory state. In vivo animal experiments prove that the components have a significant inhibitory effect on the tincture of croton oil-induced mouse ear swelling, and can be used for preventing and / or treating inflammation-related diseases.

The invention belongs to the technical field of exosomes, and discloses an exosome preparation method and application, the exosome preparation method comprises the following steps: S1, culturing target cells in an induction medium, and collecting the cells and a culture solution; s2, separating the culture solution to obtain supernate A and cell precipitate; s3, performing chromatographic purification and concentration on the supernate A to obtain the exosome; in the step S1, colchicine is also added in the process of culturing the target cells to synchronize the cell cycle; a polycaprolactone-gelatin composite microcarrier is suspended in the induction culture medium, and nicotinamide, an epidermal growth factor (EGF) and pyruvic acid are contained in the induction culture medium; the method further comprises a step S30 before the step S3, resuspending the cell precipitate obtained in the step S2 with a vesicle protection solution containing trehalose, sucrose and EDTA to obtain a supernatant B, and then combining the supernatant A with the supernatant B. According to the preparation method provided by the invention, the total secretion amount of target cells is large, the intracellular vesicle-exosome precursor can be collected, and the obtained exosome is high in concentration and low in impurity content.

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

The invention provides a tumor killing T extracellular vesicle release promoting method based on radio stimulation control, and belongs to the technical field of biological medicines.The yield of EVT secreted by T cells is remarkably increased by applying electrical stimulation to the T cells, an electrical stimulation system capable of being wirelessly controlled is established, efficient and controllable release of the T extracellular vesicles is achieved, and the tumor killing effect of the T extracellular vesicles is improved. The calcium ion dependency mechanism of the EVT is defined, and the function retention of the released EVT in tumor killing activity and tissue penetrability is verified.

This invention relates to a pharmaceutical composition for treating autoimmune diseases. The pharmaceutical composition for treating autoimmune diseases comprises an antibody and an inhibitor, wherein the antibody includes at least one of an OX40 antibody and an OX40L antibody, and the inhibitor includes at least one of a Janus kinase inhibitor and a RORγt inhibitor. In the above-mentioned pharmaceutical composition for treating autoimmune diseases, the Janus kinase inhibitor and / or the RORγt inhibitor can inhibit the secretion of IL17A by Treg cells induced by OX40 antibody and / or OX40L antibody, thereby reducing IL17A-promoted pathological inflammation and improving the efficacy of OX40 antibody and / or OX40L antibody in treating autoimmune diseases.

The present disclosure provides methods for mass tag labeling of cell secretomes and their soluble components, as well as mass-tagged soluble components of cell secretomes. In certain embodiments, the present disclosure provides methods for mass tagging of extracellular vesicles (EVs) and mass-tagged EVs. Methods of using mass-tagged soluble components of cell secretomes, such as mass-tagged EVs, mass-tagged viruses, or mass-tagged soluble proteins and peptides, are also provided. These can be combined with other labeling strategies, such as cell barcoding, that facilitate multiplex analysis and / or multidimensional analysis of the distribution, uptake, and effects of secretome components (such as EVs).

A reagent, a drug source material, a drug, a quasi-drug, a cosmetic source material, or a cosmetic that includes a supernatant of a culture solution of stem cells and is for reducing skin redness or inflammation, inflammation, number of pores, pore size, skin spots, and sebum. A reagent, a drug source material, a drug, a quasi-drug, a cosmetic source material, or a cosmetic that includes a secretion of stem cells and is for reducing skin redness or inflammation, inflammation, number of pores, pore size, skin spots, and sebum. The secretion of the stem cells may be extracellular vesicles. The secretion of the stem cells may be exosomes.

The present application provides a kind of oil composition, containing monounsaturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acid is omega-9 fatty acid;Polyunsaturated acid is the mixture of omega-6 fatty acid and omega-3 fatty acid.The present application can repair and resist aging, all-purpose skin care, increase epidermal thickness, enhance barrier, anti-inflammatory soothing, anti-wrinkle firming, soothing repair red, nourish skin, and can be applied to sensitive skin, can inhibit LPS-induced HaCaT cell IL-6 secretion, increase the thickness of 3D skin model epidermis layer, and can promote the expression of silk aggregate protein (FLG), ceramide synthase 3 (CerS3), desmoglein core glycoprotein (DSG1) which has important role for skin barrier function, indicating that it can alleviate the inflammatory response produced by LPS stimulation HaCaT cell and has enhanced skin barrier function.

The invention relates to a single-cell secretion group sample treatment device and preparation and application thereof, the device is composed of two parts: the first part is a single-cell control chip which can realize capture and culture of single cells and separation and collection of a culture solution; the second part is a propargyl functionalized capillary microreactor which can realize high-selectivity enrichment and in-situ enzymolysis of single-cell secreted protein; the two parts are integrated to construct the single cell secretion group sample treatment device. The device is combined with a high-sensitivity liquid chromatography-mass spectrometry technology, large-scale quantitative analysis of a single cell secretion group can be realized, and an important means is provided for functional heterogeneity analysis of single cells.

Systems, methods, compositions, and kits for measuring secreted factors from cells are disclosed herein, including those capable of determining single cell secretion activity and protein expression and / or gene expression simultaneously. Disclosed herein include solid supports comprising a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. Also disclosed herein include secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe. A secreted factor-binding reagent can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

A method for detecting an immune cellular response including the steps of: (a) suctioning a defined amount of the sample by an automated suction / discharge device, (b) discharging this amount, using the device, into container R, containing, beforehand, at least one stimulant for secretion of the molecule by the at least one cell, or else not containing such a stimulant, (c) when the container does not contain the stimulant beforehand, introducing into container R the at least one secretion stimulant contained in container E, using the device, and (d) allowing the sample and stimulant to incubate, forming a mixture, by the at least one cell (i) in container R or (ii) in another container S after suctioning and discharge of the mixture using the device, and (e) detecting the immune cellular response, the detection of the immune cellular response indicates the presence of an immune cellular response specific for the stimulant.

The present invention provides an acoustofluidic microfluidic chip and system, and a use thereof. The acoustofluidic microfluidic chip comprises a microporous array chip, a microfluidic channel layer, and a bulk acoustic wave resonator array chip which are sequentially stacked in a thickness direction. The acoustofluidic microfluidic chip of the present invention uses acoustofluidics to manipulate micro-objects such as cells or cell secretions, can realize accurate capture, in-situ cell culture, and selective recovery of the micro-objects, has the advantages of simple structure, low cost, high flux, high integration and the like, and has high application value.

The invention provides a double-target chimeric antigen receptor, a CAR-T cell and application of the double-target chimeric antigen receptor and the CAR-T cell, and belongs to the technical field of hybrid peptides. The double-target chimeric antigen receptor comprises EGFRvIII scFv and GRP78 scFv; the nucleotide sequence of the EGFRvIII scFv is as shown in SEQ ID NO. 2; and the nucleotide sequence of the GRP78 scFv is as shown in SEQ ID NO. 4. According to the invention, by targeting two antigen targets of EGFRvIII and GRP78, the targeting specificity is enhanced, and the ability of CAR-T cells to kill glioblastoma is enhanced. Compared with a single-target CAR-T cell (EGFRvIII-CAR-T cell or GRP78-CAR-T cell), the T cell modified by the double-target chimeric antigen receptor provided by the invention has better cell factor secretion capability and better killing effect on tumor cells.

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

The present invention relates to a secretome-based biomaterial, wherein the secretome is cell secretome selected from secreted soluble factors, apoptotic bodies, small extracellular vesicles or microvesicles that are released from cells of therapeutic interest to the cell culture medium or other fluids or combinations thereof. The invention further relates to a method for the production of the secretome-based biomaterial and to the use thereof for the treatment of diseases requiring tissue regeneration and / or immunomodulation.

The invention provides an umami peptide without nervous excitatory toxicity and a preparation process and application thereof, the umami peptide is extracted from broad bean protein, and the amino acid sequence is shown as SEQ ID NO.1 and / or SEQ ID NO.2. Compared with a traditional umami substance-sodium glutamate (monosodium glutamate MSG), the umami peptide has the characteristics of activating umami receptors TAS1R1 / TAS1R3 without acting on sodium glutamate receptors such as NMDA and the like, and has the advantages that the umami peptide can be used for preparing the umami peptide. No NMDA receptor mediated excitatory neurotoxicity exists; meanwhile, the umami peptide can stimulate intestinal endocrine cells (STC-1) to secrete GLP-1.